Loading...

Follow Cancer Network - Melanoma | For Oncologists on Feedspot

Continue with Google
Continue with Facebook
or

Valid
Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in metastatic melanoma.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center about strategies and research surrounding optimized targeted therapy in melanoma.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III United States Intergroup E1609 trial, presented at ASCO 2019.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma.
Read Full Article

Read for later

Articles marked as Favorite are saved for later viewing.
close
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Separate tags by commas
To access this feature, please upgrade your account.
Start your free month
Free Preview